Przejdź do treściPolish version: Mniej opioidów po endoprotezoplastyce kolana — różnica statystyczna bez wyraźnej korzyści klinicznej
A randomized trial in the Journal of Clinical Anesthesia illustrates an important distinction: opioid-sparing anaesthesia improved early Quality of Recovery-15 scores after total knee arthroplasty (TKA), but the difference did not reach the minimum clinically important difference (MCID).
Why this study matters
Reducing perioperative opioid exposure is part of modern enhanced recovery pathways after TKA. A statistically significant improvement in a recovery score does not necessarily represent a change that patients can meaningfully perceive. This trial helps distinguish statistical significance from clinical importance.
Study design
The randomized trial included 98 adults undergoing elective unilateral TKA. Patients, surgeons and outcome assessors were blinded. Opioid-sparing anaesthesia based on opioid-free principles (OSA) was compared with conventional opioid-based anaesthesia (OBA). Esketamine and dexmedetomidine formed the basis of the OSA regimen.
This was not completely opioid-free anaesthesia: both groups received oxycodone at skin incision and closure, a femoral nerve block, and the same postoperative multimodal analgesia and patient-controlled analgesia. The primary outcome was QoR-15 at 24 hours. Other outcomes included QoR-15 at 48 hours, Oxford Knee Score (OKS), EQ-5D-3L, postoperative nausea and vomiting, CRP, and selected outcomes at 1 and 3 months.
Main results
- Mean QoR-15 at 24 hours was 118.4 ± 11.5 with OSA and 113.3 ± 12.2 with OBA; adjusted difference 5.12 points (95% CI 0.51–9.74; P = 0.029).
- At 48 hours the adjusted difference remained statistically significant: 5.54 points (95% CI 1.57–9.52; P = 0.007).
- OSA was associated with less postoperative nausea and vomiting and lower CRP.
- At 1 month, OKS was statistically better with OSA by 2.31 points (95% CI 0.34–4.27; P = 0.022).
- No significant differences were found in the other secondary outcomes reported in the abstract.
Clinical interpretation for an orthopaedic surgeon
The authors’ central conclusion is that the QoR-15 difference did not reach the MCID. The trial supports reducing opioid exposure within a well-designed multimodal regimen, but does not demonstrate a large, clearly perceptible improvement in recovery. It favours judicious opioid reduction rather than adoption of one regimen for every patient undergoing TKA.
Limitations
- This was a single-centre trial with a relatively small sample of 98 patients.
- Two complex protocols were compared, so the effects cannot be attributed to an individual drug.
- The regimen based on opioid-free principles still included opioids in both arms.
- The main QoR-15 difference remained below the threshold for a minimally important clinical change.
- The public abstract does not allow the same assessment of protocol details and additional analyses as the full text.
Implications for practice
The findings support multimodal analgesia and opioid reduction after TKA, particularly when nausea and vomiting can be reduced without compromising pain control. They do not establish the superiority of entirely opioid-free anaesthesia, justify routine esketamine plus dexmedetomidine for everyone, or warrant direct extrapolation to other ERAS pathways, regional blocks or high-risk populations.
References
Liu J, Liu J, Liu P, et al. Opioid-sparing anesthesia based on opioid-free principles for early recovery after total knee arthroplasty: A randomized controlled trial. Journal of Clinical Anesthesia. Published online 22 August 2026;114:112307. PMID: 42632160. DOI: 10.1016/j.jclinane.2026.112307. PubMed record.
This summary is based on the public abstract.
Related resources
For Doctors and Physiotherapists · Research Updates, Literature and Evidence-Based Medicine
Content prepared by: Tomasz Poboży - orthopaedic surgeon.